UCalgary: University of Calgary Joins the Phase II Trial of LSALT

TORONTO, March 15, 2024 (GLOBE NEWSWIRE) - Arch Biopartners Inc., ("Arch" or the "Company") (TSX Venture: ARCH and OTCQB: ACHFF), announced today that a research team from the University of Calgary's Cumming School of Medicine has joined the Phase II trial for LSALT peptide targeting the prevention and treatment of cardiac surgery-associated acute kidney injury [...]